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Summary
Background:  Studies  about  the  pathogenesis  of  bronchial  hyperreactivity  (BHR)  in  patients  with
persistent  allergic  rhinitis  (PAR)  and  its  relationship  with  lower  airway  remodeling  are  extremely
limited.
Objective:  This  study  evaluated  bronchial  vascular  remodeling  via  the  measurement  of  angio-
genic factor,  vascular  endothelial  growth  factor-A  (VEGF-A),  and  anti-angiogenic  factor,
Endostatin,  and  evaluated  their  relationship  with  BHR  in  patients  with  PAR.
Methods:  The  study  group  consisted  of  30  patients  with  PAR  monosensitized  to  house  dust
mites and  14  non-allergic  healthy  controls.  All  subjects  underwent  induced  sputum  and  metha-
choline (M)  bronchial  provocation  tests.  VEGF-A  and  Endostatin  levels  were  measured  by  ELISA
in induced  sputum  supernatants.
Results:  The  percentages  of  eosinophils  in  induced  sputum  were  significantly  increased  in
patients with  PAR  compared  with  healthy  controls.  There  were  no  significant  differences
between patients  with  PAR  and  healthy  controls  in  terms  of  levels  of  VEGF  (37.9  pg/ml,
min--max: 5--373  pg/ml  vs.  24.9,  min--max:  8--67  pg/ml,  p  =  0.8  respectively),  Endostatin The study was approved by the local ethics committee, and written informed consent was obtained. The study was supported by Ankara
University Research Fund (project number: 09B3330019).
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(532.5  pg/ml,  min--max:  150--2125  pg/ml  vs.  644,  min--max:  223--1123  pg/ml,  p  =  0.2  respec-
tively) and  VEGF/Endostatin  ratio  (0.057  vs.  0.045,  p  =  0.8  respectively).  In  addition,  there
were no  significant  differences  between  patients  who  are  BHR  positive  (n  =  8),  or  negative  to
M (n  =  22)  in  terms  of  levels  of  VEGF,  Endostatin  and  VEGF/Endostatin  ratio  and  no  correlations
among value  of  PD20  to  M  and  levels  of  VEGF,  Endostatin  and  VEGF/Endostatin  ratio.
Conclusion:  We  conclude  that  VEGF-A  and  Endostatin  did  not  differ  between  patients  with  PAR
and healthy  controls  regardless  of  BHR  to  M.
© 2014  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.U.  All  rights
reserved.
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he  presence  of  inflammation  and  airway  remodeling  are
ornerstones  in  the  pathogenesis  of  asthma.1,2 Angiogenesis
as  recently  attracted  considerable  attention  as  a  com-
onent  of  airway  remodeling  in  bronchial  asthma.  One  of
he  key  molecules  for  angiogenesis  is  VEGF;  it  is  widely
xpressed  within  many  highly  vascularized  organs  including
he  lungs  and  is  a  potent  inducer  of  endothelial  cell  growth.3
ascular  remodeling  and  increased  expression  of  associated
rowth  factors  such  as  VEGF  are  well-recognized  features
f  asthma.4,5 Endostatin  is  a  strong  endogenous  inhibitor
f  angiogenesis  and  is  produced  by  various  types  of  cells.6
ndostatin  specifically  inhibits  endothelial  cell  growth  and
igration  and  directly  antagonizes  the  biological  effects  of
EGF.7 The  vascular  component  of  remodeling  is  regulated
y  a  balance  between  angiogenic  and  anti-angiogenic  fac-
ors.  However,  there  are  no  data  regarding  the  balance  of
ajor  angiogenic  and  anti-angiogenic  factors  in  the  lower
irways  of  patients  with  allergic  rhinitis  (AR)  without  con-
omitant  asthma.
AR,  which  is  particularly  associated  with  bronchial  hyper-
eactivity  (BHR),  is  considered  as  a  risk  factor  for  asthma
evelopment.8,9 The  mechanism  of  BHR  in  AR  is  not  fully
nderstood  and  it  is  not  known  whether  the  BHR  in  asthma
nd  AR  have  the  same  pathophysiologies.  Studies  on  the
athogenesis  of  BHR  in  patients  with  AR  and  its  relationship
ith  lower  airway  remodeling  are  extremely  limited.10--13
n  our  first  trial,  we  evaluated  bronchial  vascular  remod-
ling  and  its  relationship  with  BHR  via  measurement  of
EGF-A  and  Endostatin  levels  in  allergic  rhinitis  patients
onosensitized  to  pollen.10 In  the  present  study,  bronchial
ascular  remodeling  parameters  and  their  relationship  with
HR  were  evaluated  by  measuring  the  same  angiogenic/anti-
ngiogenic  factors  in  patients  with  persistent  allergic  rhinitis
PAR).
ethods
ubjectsnclusion  criteria  for  patients  with  rhinitis  were  as  follows:
1)  a  history  of  persistent  rhinitis  without  cough,  wheezing,
r  shortness  of  breath  during  natural  exposure,  (2)  positive
d
b
d
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xpiratory  volume  in  1  second  (FEV1) greater  than  80%  of
redicted  value.  Pulmonary  function  tests,  Bronchial  Provo-
ation  Test  (BPT)  to  methacholine  (M)  and  induced  sputum
ere  performed.  All  subjects  denied  any  past  or  present
ymptoms  suggestive  of  asthma  including  intermittent  dys-
nea,  wheezing,  or  a recurrent  cough,  and  any  respiratory
nfection  during  the  month  preceding  this  study.  Control  sub-
ects  had  normal  spirometry  and  airway  responsiveness  to  M
PC20 >  16  mg/ml),  had  negative  skin  prick  test  to  common
nhalant  allergens,  no  history  of  rhinitis,  no  current  or  past
ymptoms  suggesting  asthma,  and  no  respiratory  infection
uring  the  month  before  enrollment.  Patients  and  controls
ere  all  nonsmokers  and  were  free  of  all  systemic  diseases
nd  malignancies.  None  had  eczema  or  history  of  nasal  poly-
osis.  None  of  the  patients  had  previously  been  treated
ith  immunotherapy.  All  patients  discontinued  their  medi-
ations  (nasal  steroid  and  oral  antihistamine)  at  least  1  week
efore  M  BPT,  but  they  were  allowed  to  use  nasal  antihis-
amine  spray  if  necessary.  Patients  were  classified  according
o  the  Allergic  Rhinitis  and  its  Impact  on  Asthma  (ARIA)
uidelines.14 The  study  was  approved  by  Ankara  University
edical  School’s  Ethics  Committee  (Decision  No:  152-4759).
valuation  of  atopy
kin  prick  tests  were  performed  by  using  a  common  panel,
ncluding  D.  pteronyssinus,  D.  farinae, grass,  tree,  and  weed
ollens,  cat,  dog,  Alternaria,  Cladosporium, and  cockroach
llergen  extracts  (Allergopharma,  Stockholm,  Sweden).
he  positive  and  negative  controls  used  were  histamine
10  mg/mL)  and  phenolated  glycerol  saline,  respectively.  A
ean  wheal  diameter  of  3  mm  or  greater  than  that  obtained
ith  the  control  solution  was  considered  positive.
ulmonary  function  tests  and  nonspecific  bronchial
rovocation  test
ulmonary  function  tests  (Flowhandy  Zan  100  USB,
ermany)  were  performed  before  sputum  induction  to
etermine  baseline  FEV1.  BPT  using  M  was  performed
etween  8:30  and  10:30  AM  according  to  the  method
escribed  by  Cockcroft  et  al.15 After  inhalation  of  physio-
ogic  saline,  patients  inhaled  doubling  concentrations  of  M
com by Elsevier on September 26, 2019.
. Elsevier Inc. All rights reserved.
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iVEGF-A,  Endostatin  levels  in  patients  with  PAR  
from  0.25  to  16  mg/mL  diluted  in  physiologic  saline.  The
challenge  was  stopped  when  the  FEV1 decreased  by  more
than  20%  from  the  post  saline  level  or  when  the  highest
concentration  of  M  had  been  administered.  The  result  was
expressed  as  PC20 M.  The  PC20 M  was  calculated  from  the
log  concentration  response  curve  by  linear  interpolation  of
the  two  last  points.  A  PC20 M  of  more  than  16  mg/mL  was
accepted  as  the  cutoff  point.16
Sputum  induction  and  processing
Sputum  induction  was  performed  between  9  and  10  AM
according  to  the  method  proposed  by  Pizzichini  et  al.  and
slightly  modified  and  adapted  according  to  Pavord  et  al.17,18
Sputum  induction  was  applied  at  least  three  days  after  the
M  BPT.  Before  inhalation  of  hypertonic  saline  solution,  all
patients  inhaled  2 puffs  of  salbutamol  200  g  (VentolinTM,
GSK,  UK)  administered  through  a  metered  dose  inhaler
and  underwent  spirometry  10  min  later.  Then  an  aerosol  of
sterile  3%  saline  solution  was  generated  by  an  ultrasonic  neb-
ulizer  (output  set  at  1  ml/min,  Omron  NE-U17,  Japan)  and
inhaled  for  7  min  through  a  mouthpiece  without  a  valve  or
nose  clip.  If  the  patient  could  not  expectorate  at  this  stage,
the  concentration  of  saline  was  increased  gradually  accord-
ing  to  the  decrease  in  FEV1  measurements  from  baseline.  In
case  of  a  less  than  10%  decrease  in  FEV1,  the  concentration
of  saline  was  increased  from  3%  to  4%  and  then  to  5%.  Spu-
tum  induction  was  performed  three  times.  After  each  period
of  inhalation,  patients  were  asked  to  rinse  their  mouths  and
throats  carefully,  swallow  the  water,  and  blowing  the  nose
before  expectoration  to  minimize  contamination  with  saliva
and  postnasal  drip.  They  were  encouraged  to  cough  deeply
at  3  min  intervals  thereafter.  The  sputum  was  collected
into  a  container.  The  collected  sputum  was  pooled  and
immediately  processed.  The  volume  of  the  entire  sputum
sample  was  determined,  and  an  equal  volume  of  0.1%  dithio-
threitol  (Sputolysin  R;  Calbiochem,  San  Diego,  CA,  USA)
was  added.  The  sputum  samples  were  mixed  gently  with
a  vortex  mixer  and  incubated  for  15  min  at  room  tempera-
ture  to  ensure  complete  homogenization.  Sputum  viability
was  determined  with  the  trypan  blue  exclusion  method  to
ensure  that  viability  was  adequate  and  then  filtered  sputum
was  centrifuged  at  450  ×  g  for  10  min  (Rotina  38R  Hettich,
Germany).  The  resulting  cell  pellets  were  resuspended  in
phosphate  buffer  saline.  A  total  cell  count  was  carried  out
using  a  hemocytometer  and  cell  concentrations  were  then
adjusted  to  1.0  ×  106 cells/ml.  Slides  were  stained  with  May-
Grünwald--Giemsa  stain  for  differential  cell  counts  which
were  performed  by  the  counting  of  400  nonsquamous  cells  by
a  cytologist  in  a  manner  blind  to  clinical  details.  The  super-
natant  was  stored  at  −80 ◦C  (Sanyo  freezer  MDF-U3086S,
Japan)  for  subsequent  assays  for  VEGF  and  Endostatin.
Inflammatory  cell  counts  and  angiogenic  mediators
in induced  sputumFour  hundred  cells  were  counted  in  each  slide,  and  inflam-
matory  cells  (macrophages,  neutrophils,  lymphocytes,  and
eosinophils)  were  determined  as  percentages  of  the  total
cells  using  light  microscopy  (400×).
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Vascular  endothelial  growth  factor  (Human  VEGF-A  ELISA,
ender  MedSystems  GmBH,  Vienna,  Austria)  and  Endostatin
Quantikine®, Human  Endostatin  Immunoassay,  R&D  system
nc.,  Minneapolis,  USA)  were  measured  by  ELISA  using  a  spe-
ific  ELISA  kit  according  to  the  manufacturer’s  instructions
n  induced  sputum  supernatant.  VEGF-A  and  Endostatin  con-
entrations  were  quantitated  by  comparison  with  a  standard
urve  generated  using  recombinant.  The  detection  limits
ere  as  follows:  VEGF-A  7.9  pg/ml,  Endostatin  23  pg/ml.
he  intra-  and  inter-assay  variabilities  were,  respectively,
EGF-A  6.8  and  8.3%,  Endostatin  6.9  and  7.9%.
tatistics
ata  are  expressed  as  median  and  min--max.  Differences
mong  groups  were  examined  by  means  of  Kruskal--Wallis
nd  Mann--Whitney  U-tests.  The  significance  of  correlations
as  evaluated  by  determining  the  Spearman’s  rho  correla-
ion  coefficients.  A  significance  level  was  taken  as  0.05  while
esting  the  hypothesis.  Data  were  analyzed  using  SPSS  v.  11.5
SPSS  Inc.,  Chicago,  IL,  USA).
esults
 total  of  42  patients  with  PAR  and  22  healthy  con-
rols  were  included  in  this  study.  All  patients  had  severe
ersistent  allergic  rhinitis  according  to  the  current  ARIA
lassification.14 Sufficient  sputum  samples  were  provided  in
0  of  the  42  PAR  patients  (F/M:  21/9,  mean  age:  31.9  ±  11.4
ears)  and  14  of  the  22  controls  (F/M:  5/9,  mean  age:
0.6  ±  6.3  years).  There  were  no  significant  differences
etween  patients  and  healthy  controls  in  terms  of  age,
EF25--75,  and  FEV1 value,  weight  of  the  entire  sputum  and
ell  viability,  but  female  gender  was  significantly  higher  in
he  PAR  group  (p  =  0.049)  than  in  the  controls.  Cell  viability
as  >50%  in  the  all  subjects.  Eight  PAR  patients,  but  none
f  the  controls,  were  positive  for  PC20 M  (PC20M  <16  mg/ml).
he  patients  were  divided  into  two  groups  according  to  the
resence  or  absence  of  BHR.  There  were  no  significant  dif-
erences  between  patients  with  or  without  BHR  and  controls
n  terms  of  sex,  age,  time  of  rhinitis  symptoms  and  diagno-
is,  FEF25--75, and  FEV1 value,  weight  of  the  entire  sputum
nd  cell  viability  (Table  1).
A  significantly  greater  number  of  eosinophils  were  found
n  the  sputum  of  PAR  patients  compared  to  the  nonaller-
ic  controls,  their  median  (min--max)  percentage  counts
eing  0.5  (0--7)  and  0  (0--0.2)  (p  <  0.001),  respectively.  No
ignificant  differences  were  observed  for  other  cell  types
etween  controls  and  patients  with  PAR.  The  percentages
f  eosinophils  in  the  induced  sputum  were  significantly
ncreased  in  PAR  patients  with  BHR  compared  to  PAR  patients
ithout  BHR  and  controls  (p  <  0.001).  No  significant  dif-
erences  were  observed  for  other  cell  types  among  the
hree  groups  (Table  2).  There  was  no  significant  correlation
etween  the  number  of  eosinophils  and  PC20 M  value.
The  median  levels  of  VEGF  were  not  statistically  higher
n  PAR  patients  than  in  healthy  controls  (37.9  pg/ml,
in--max:  5--373  pg/ml  vs.  24.9,  min--max:  8--67  pg/ml,
 =  0.8  respectively).  Similarly,  the  median  levels  of  Endo-
tatin  were  not  significantly  higher  in  patients  with  PAR  than
n  healthy  controls  (532.5  pg/ml,  min--max:  150--2125  pg/ml
ey.com by Elsevier on September 26, 2019.
019. Elsevier Inc. All rights reserved.
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Table  1  Patients’  demographic,  clinical,  functional  respiratory,  and  induced  sputum  data.
BHR  (+)  PAR
n: 8
BHR  (−)  PAR
n:  22
Controls
n:  14
P-Value
Sex  (M/F)  6/2  15/7  9/5  >0.05
Age, years  35  ±  4.4  30.6  ±  13.2  30.6  ±  6.3  >0.05
Time of  rhinitis  symptoms,  months  12  (5--12)  12  (5--12)  --  >0.05
Time of  diagnosis,  years  3.6  ±  2.1  4.4  ±  2.7  --  >0.05
Wheal of  D.pteronyssinus,  mm  4.5  ±  0.5  5.3  ±  2.3  --  >0.05
Wheal of  D.  farinae,  mm  4.7  ±  1.9  5  ±  2.1  --  >0.05
PC20 M,  mg/ml  6.2  ±  4.8  >16  >16
FEV1,  % 96.1  ±  10.1 98.6  ±  9.9 104.1  ±  7,9 >0.05
FEF25--75,  % 84.8  ±  21.3 93.1  ±  18.3 102.8  ±  22.1 >0.05
Weight of  sputum,  gr 2.2  ±  0.8 2.5  ±  1.3 3  ±  1.3 >0.05
Cell viability,  %  83.6  ±  8.6  83.5  ±  19.2  77.8  ±  16  >0.05
Results are expressed as means ± SD for age, time of diagnosis, wheal of Der p, wheal of Der f, FEV1, FEF25--75, weight of sputum, cell
viability and PC20 M values are expressed as geometric means ± SD. Results are expressed as median (min--max) for time of rhinitis
symptoms. BHR (−) PAR, pesistent allergic rhinitis patients without BHR; BHR (+) PAR, persistent allergic rhinitis patients with BHR; M,
methacholine.
Table  2  Cell  counts  in  the  induced  sputum  of  control  and  rhinitis  subjects  with  or  without  BHR.
BHR  (+)  patients  with  PAR  BHR  (−)  patients  with  PAR  Controls
Total  cell  number/mL  of  sputum  1.1  (0.4--3.8)  1.0  (0.4--2.8)  1.2  (0.4--3.6)
Eosinophils, %  (min--max)  2.9  (0.3--7)* 0.4  (0--1.6)** 0  (0--0.2)
Macrophages  %  (min--max)  62.5  (52--86)  78  (52--92)  70.9  (42.5--92)
Neutrophils %  (min--max)  30.5  (10--42)  20  (5.5--46)  26.7  (7.5--54.8)
Lymphocytes  %  (min--max)  1  (0--8)  1.2  (0--3.8)  1  (0.2--6)
* Significantly different from the values for control subjects and PAR patients without BHR (p < 0.001).
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parentheses.
s.  644,  min--max:  223--1123  pg/ml,  p  =  0.2  respectively).
he  VEGF/Endostatin  ratio  was  not  statistically  higher  in
atients  with  PAR  than  in  healthy  controls  (0.057  vs.  0.045,
 =  0.8  respectively).  These  results  show  that  there  was  no
tatistical  difference  between  groups.  In  addition,  there  no
ignificant  differences  between  patients  who  were  BHR  pos-
tive  (n  =  8)  or  negative  to  M  (n  =  22)  and  controls  in  terms  of
evels  of  VEGF,  Endostatin  and  VEGF/Endostatin  ratio.  There
ere  no  correlations  among  value  of  PD20  to  M  and  levels  of
EGF,  Endostatin  and  VEGF/Endostatin  ratio.
iscussion
his  is  the  first  study  about  the  levels  of  VEGF-A,  Endo-
tatin,  and  the  VEGF-A/Endostatin  ratio  in  induced  sputum
n  patients  with  PAR.  The  levels  of  VEGF-A,  Endostatin  and
he  ratio  of  VEGF-A/Endostatin  were  not  significantly  differ-
nt  between  patients  with  PAR  and  healthy  controls.  There
ere  no  significant  differences  between  patients  with  or
ithout  BHR  to  M  and  controls  in  terms  of  levels  of  VEGF,
ndostatin  and  VEGF/Endostatin  ratio.  The  only  significant
ifference  between  patients  and  controls  was  the  increased
umber  of  sputum  eosinophils  in  patients  with  PAR.
Although  the  inflammatory  pathogenesis  of  BHR  is  under-
tood  in  asthmatic  patients,  light  has  not  been  shed  on
he  precise  mechanism  of  BHR  in  patients  with  AR.11,19,20
o
d
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n  our  trial,  we  demonstrated  higher  eosinophil  numbers  in
atients  with  PAR  compared  to  healthy  controls  indepen-
ent  of  BHR,  as  in  previous  studies  including  our  first  study
n  allergic  rhinitis  patients  monosensitized  to  pollen.10,21--25
lso,  the  percentage  of  eosinophils  in  induced  sputum  was
ound  to  be  significantly  higher  in  PAR  patients  with  BHR
hen  compared  with  those  without  BHR  The  presence  of
putum  eosinophils  in  our  patients  seemed  to  be  linked  to
he  presence  of  both  AR  and  BHR.  However,  no  correlation
etween  PC20 M  values  and  eosinophil  levels  was  observed.
his  may  be  related  to  a  probable  correlation  between  air-
ay  inflammation  and  other  indirect  agents  of  BPT  such  as
denosine  but  not  M.  the  limited  number  of  patients  with
AR  with  BHR  may  be  other  factor  affecting  the  lack  of  cor-
elation  between  PC20 M.  On  the  other  hand,  eosinophils  may
ot  be  the  only  inflammatory  cells  responsible  for  the  devel-
pment  of  BHR  when  we  consider  the  fact  that  the  anti-IL-5
ntibody  decreased  peripheral  blood  and  sputum  eosinophil
evels  but  nevertheless  had  no  effect  on  BHR  in  asthmatic
atients.26 These  findings  imply  that  other  pathologies  may
nderlie  the  main  mechanism  of  BHR  apart  from  eosinophilic
nflammation  of  the  lower  airways  in  AR  patients,  as  already
hown  in  asthma.Previous  studies  examining  bronchial  biopsies  have  ruled
ut  inflammation  as  the  single  factor  responsible  for  the
evelopment  of  BHR  and  have  supported  structural  changes
lay  a  role  in  this  process.27--29 Even  though  there  have  been
com by Elsevier on September 26, 2019.
. Elsevier Inc. All rights reserved.
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RVEGF-A,  Endostatin  levels  in  patients  with  PAR  
numerous  studies  reporting  airway  remodeling  in  asthma,
only  a  few  of  them  have  researched  airway  remodeling  in
patients  with  AR.  In  these  studies  collagen  deposition  was
demonstrated  in  bronchial  biopsies  and  this  was  thought  to
be  responsible  for  RBM  thickness  in  AR  patients.12,13 Some
of  the  drawbacks  encountered  in  these  studies  included  dif-
ficulties  in  technical  application,  lack  of  sufficient  samples
or  the  inability  of  samples  to  mirror  the  whole  lower  airway
which  in  turn  could  make  the  evaluation  of  inflammation  and
lower  airway  remodeling  using  bronchial  biopsies  imprac-
tical.  In  this  respect,  current  research  has  focused  on  the
use  of  non-invasive  techniques  such  as  induced  sputum  that
could  possibly  reflect  inflammation  remodeling  of  the  lower
airway.  A  recent  study  carried  out  with  induced  sputum
showed  that  AR  patients  have  increased  VEGF  mRNA  lev-
els  compared  to  healthy  controls.11 In  another  recent  study
conducted  with  induced  sputum,  AR  patients  were  found  to
have  significantly  higher  VEGF  levels  compared  to  healthy
controls.25 In  these  studies,  the  possibility  of  angiogenesis
in  the  lower  airway  tract  of  non  asthmatic  patients  with  AR
was  indicated.
Although  angiogenesis  is  regulated  by  a  balance  of  angio-
genic  and  anti-angiogenic  factors.3,30--32 the  relative  levels
of  antiangiogenic  factors  (Endostatin)  in  the  lower  airways
of  patients  with  AR  have  only  recently  been  evaluated  by
our  group.10 This  study  compared  data  obtained  during  the
pollen  season  from  patients  monosensitized  to  pollen  with  or
without  BHR  to  M  and  healthy  controls;  it  was  found  that  the
levels  of  VEGF-A  and  the  ratio  of  VEGF-A/Endostatin  were
significantly  higher  and  the  level  of  endostatin  was  signifi-
cantly  lower  in  allergic  rhinitis  patients  monosensitized  to
pollen  with  BHR.10 However,  contrary  to  our  expectations,  in
the  present  trial,  neither  the  parameters  of  vascular  remod-
eling  nor  their  association  with  BHR  could  be  demonstrated
in  patients  with  PAR  monosensitized  to  house  dust.  We  spec-
ulate  that  the  reason  for  this  may  be  multifactorial,  such  as
the  duration  and  intensity  of  allergen  exposure,  severity  and
duration  of  symptoms.  Severity  of  the  rhinitis  did  not  seem
to  be  a  factor  since  all  subjects  in  the  current  study  and
almost  all  subjects  in  our  previous  trial  had  severe  rhinitis.
VEGF  is  not  only  a  remodeling  mediator  but  also  a  media-
tor  of  inflammation  because  it  has  specifically  been  shown
to  increase  Th2-mediated  inflammation.33 Therefore,  in  our
first  trial  we  speculated  that  the  high  levels  of  VEGF  in  the
induced  sputum  of  patients  with  monosensitized  to  pollen
during  the  pollen  season  might  be  associated  with  increased
allergic  inflammation  in  this  season.  However,  in  the  present
study,  we  did  not  check  the  duration  and/or  intensity  of  dust
mite  allergen  exposure  in  the  homes  and/or  workplaces  of
patients  with  PAR.  Evaluation  of  the  relationship  between
these  levels  and  the  results  of  induced  sputum  could  have
yielded  more  reliable  results.
The  main  limitation  of  the  current  study  was  the  indirect
evaluation  of  vascular  remodeling  based  on  only  two  growth
factors  and  the  absence  of  direct  histopathological  studies
from  the  lower  airway.  However,  previous  studies  found  a
correlation  between  measured  vascular  remodeling  param-
eters  (VEGF,  MMP-9)  using  induced  sputum  and  parameters
measured  with  bronchial  biopsy.34,35 Although  ethical  issue
and  technical  concerns  seem  to  be  obstacles  in  widely  use
of  bronchoscopy  in  routine  practice  and  research  settings  in
patients  with  allergic  rhinitis,  future  studies  with  bronchial
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iopsy  and  BAL  including  other  potential  factors  contribut-
ng  angiogenesis  could  reinforce  our  data.  Another  limitation
as  the  limited  number  of  patients  with  PAR,  particularly
ases  with  BHR  to  M.  Although  the  mean  level  of  VEGF-A  and
atio  of  VEGF-A/Endostatin  were  higher  in  PAR  patients  than
n  healthy  controls,  the  differences  were  not  statistically
ignificant.  This  was  the  case  for  the  mean  level  of  Endo-
tatin  as  well.  Inability  to  obtain  statistically  significant  data
nd  the  correlation  among  PC20 M  value  and  levels  of  VEGF-
,  Endostatin,  and  VEGF-A/Endostatin  ratio  may  be  related
o  this  numerical  restriction  and  larger  patient  numbers  may
ead  to  more  meaningful  results.
In  conclusion,  based  on  in  induced  sputum  samples,
here  was  eosinophilic  inflammation  in  the  lower  airway  of
atients  with  PAR  with  more  remarkable  inflammation  in  PAR
atients  with  BHR  but  its  correlation  with  PC20 M  value  could
ot  be  demonstrated.  However,  levels  of  VEGF-A  and  endo-
tatin  did  not  differ  between  patients  with  PAR  and  healthy
ontrols  regardless  of  BHR  to  M.  These  non-invasive  find-
ngs  should  be  confirmed  in  a  larger  and  well  defined  study
opulation  along  with  systemic  biomarkers
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